<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022602</url>
  </required_header>
  <id_info>
    <org_study_id>Gen 2 - 01</org_study_id>
    <nct_id>NCT05022602</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System</brief_title>
  <official_title>Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seno Medical Instruments Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Radiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seno Medical Instruments Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study performs the first clinical evaluation of the Gen 2 Imagio System in a clinical&#xD;
      setting to assess image quality with both the IUS ultrasound only probe and the OA/US (duplex&#xD;
      probe).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Obtain ultrasound only probe images and duplex probe OA/US (both gray scale and OA)&#xD;
           probe images. This includes doppler and elastography imaging with the gray scale only&#xD;
           ultrasound probe and ultrasound mode of the duplex OA/US probe.&#xD;
&#xD;
        2. Provide breast and lymph node pathology results (except BI-RADS 1, 2 and 3 (as&#xD;
           applicable))&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imagio Imaging of breast mass and lymph nodes as applicable</measure>
    <time_frame>Baseline</time_frame>
    <description>Obtain ultrasound only probe images and OA/US (both gray scale and OA) probe images. This includes doppler and elastography imaging with gray scale only ultrasound probe and ultrasound mode of the duplex OA/US probe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathology Results</measure>
    <time_frame>Baseline</time_frame>
    <description>Provide breast and lymph node pathology results (except BI-RADS 1, 2 and 3 (as applicable))</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Breast Cancer Stage</condition>
  <arm_group>
    <arm_group_label>Imagio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imagio Grayscale only probe and Imagio Duplex probe in ultrasound only and OA modes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imagio</intervention_name>
    <description>Imagio - both ultrasound probe and Duplex OA probe</description>
    <arm_group_label>Imagio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has a signed and dated informed consent, prior to initiation of any study-related&#xD;
             activities.&#xD;
&#xD;
          2. Is at least 18 years of age.&#xD;
&#xD;
          3. Have been referred for a breast US because of a breast lesion/mass finding via a&#xD;
             palpable lump or per standard of care imaging.&#xD;
&#xD;
          4. Is willing and able to comply with protocol-required scans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is pregnant or lactating.&#xD;
&#xD;
          2. Has a condition or breast impediment (i.e. insect bites, poison ivy, rash, open&#xD;
             wounds, chafing of the skin, scar, tattoos, moles, hematoma, nipple rings, etc.) which&#xD;
             could interfere with the intended field of view.&#xD;
&#xD;
          3. Is experiencing photo-toxicity associated with currently taking, or having taken,&#xD;
             photosensitizing agents within the previous 72 hours such as some sulfur containing&#xD;
             drugs, ampicillin, tetracycline.&#xD;
&#xD;
          4. Is currently undergoing phototherapy.&#xD;
&#xD;
          5. Has a history of any photosensitive disease (e.g., porphyria, lupus erythematosus) or&#xD;
             undergoing treatment for a photosensitive disease and is experiencing&#xD;
             photosensitivity.&#xD;
&#xD;
          6. Has had an adverse reaction in the past to medical laser procedures, such as laser&#xD;
             hair removal or laser tattoo removal.&#xD;
&#xD;
          7. Has had prior benign excisional breast biopsy on breast of interest within the past 18&#xD;
             months.&#xD;
&#xD;
          8. Currently has mastitis.&#xD;
&#xD;
          9. Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pam Otto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaan Schaeffer</last_name>
    <phone>6106983259</phone>
    <email>sschaeffer@senomedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Health</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Otto, MD</last_name>
      <phone>210-567-5558</phone>
      <email>ottop@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

